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Review
In Canada, two blood services are responsible for the 
provision of all blood components: Héma-Québec for the 
province of Québec and Canadian Blood Services (CBS) for the 
rest of Canada. There is close collaboration between the two 
organizations to ensure the provision of rare blood units; units 
are shipped between the two blood services when necessary. 
This article will focus on the rare donor program at CBS. CBS 
has approximately 425,000 active donors (donors who have 
donated in the past 18 months) who donate approximately 
900,000 red blood cell (RBC) units per year. Of these, 
approximately 2,000 donors have a rare donor code, and 800 
RBC units are found in the frozen rare inventory. The inventory 
is managed nationally, with units being sent throughout the 
country wherever they are needed.  
Methods of Donor Screening, Recruitment, and 
Retention
Potential rare donors are found by several mechanisms. 
Close to 45,000 donors (approximately 10% of the active donor 
base), chosen based on ABO group, D type, and donation status, 
are phenotyped annually using an automated solid-phase 
platform, supplemented by manual testing. Implementation of 
the Immucor (Norcross, GA) NEO permits automated testing 
for the 11 common antigens (C, E, c, e, K, Fya, Fyb, Jka, Jkb, S, 
and s). When the typings have been performed on two separate 
donations, the phenotype will print on the donation label for 
all subsequent donations. Genotyping using an automated 
testing platform (Progenika-Grifols IDCore XT; San Marcos, 
TX) is done on samples with phenotypes of particular interest, 
such as group O, D− S− s−, or group O, D− Fy(a−b−), to 
identify rare donors. Genotyping is also being performed on 
samples from clinics with a high number of ethnically diverse 
donors and donors known to be missing a high-prevalence 
antigen originally typed using unlicensed serological reagents. 
Genotyping will be increasingly important to type donors of 
African origin, as there is an increasing need for RBC units to 
provide transfusion support for patients with sickle cell anemia. 
Identification of ethnically diverse donors for genotyping 
will be facilitated by the introduction of a voluntary question 
regarding donor ethnic origin in 2016. When an antibody to a 
high-prevalence antigen is identified in a prenatal patient, we 
attempt to recruit the individual to become a blood donor when 
she becomes eligible. We also attempt to obtain samples from 
family members of prenatal patients as well as patients with 
rare types identified by our diagnostic services laboratories. 
Testing of prenatal patients and family members of prenatal 
and diagnostic services patients has enabled us to find several 
rare donors whose phenotypes are not found on the automated 
genotyping platform, such as GE:−2,−3; Jr(a−); and Vel−.
We do not provide any incentives for rare donors. At 
the present time, these individuals are simply sent a letter 
explaining how rare their blood is. Often, they are contacted by 
phone to provide units for a given patient. We hope to develop 
more robust donor loyalty programs to retain these donors 
going forward.
Current Inventory, Imports, Exports, and 
Challenges
At the present time, we have 801 RBC units in our rare 
phenotype inventory (Table 1). On average, approximately 30 
RBC units are deglycerolized every year. We currently have no 
Rhnull donors.
From 2011 through December 31, 2014, we imported 26 
rare units from other countries and 9 rare units from Héma-
Québec. Imported rare units included 7 K0, 5 Jk(a−b−), 3 I−E−, 
4 Co(a−), 2 Jr(a−), 2 Di(b−), 1 Rhnull, and 2 that were negative 
for multiple antigens. The American Rare Donor Program has 
graciously provided most of the international units imported, 
with the K0 units coming from Japan and Finland, and the 
Rhnull unit coming from South Africa. Over the years, we have 
exported a small number of units including Bombay units to 
Australia and Kp(b−) Jk(b−) units to the United States.
We have had very few incompatible transfusion cases. In 
2010, we were challenged by a patient who required AnWj− 
units.1 We provided units that were truly AnWj− or expressed 
the In(Lu) phenotype. These units came from our own donors, 
as well as from Héma-Québec and international donors. We 
were unable to find crossmatch-compatible units for a pregnant 
female with sickle cell anemia with multiple alloantibodies 
and other unidentified reactivity; this may have contributed 
to fetal loss. We are currently challenged to provide adequate 
transfusion support for patients with sickle cell anemia with 
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partial CE antigens and multiple antibodies requiring chronic 
transfusion support. We also have an inadequate number of 
Di(b−) donors; many Di(b−) individuals are part of the native 
Canadian population and live in remote areas.
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Table 1. Frozen red cell inventory, Canadian Blood Services, 
March 2015 (N = 801)























* Over 150 known donors; only units negative for several other antigens were 
frozen. 
† Over 1500 known donors; only units negative for several other antigens 
were frozen.
‡Mainly rare phenotype combinations.
